Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules by Vormann, M.K. et al.
Research Article
Theme: Adding the T to ADME: Predictive Toxicity in Renal Drug Development
Guest Editors: Rosalinde Masereeuw and Raymond Lai
Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal
Tubules
Marianne K. Vormann,1 Linda Gijzen,1 Simon Hutter,1 Lisette Boot,1 Arnaud Nicolas,1
Angelique van den Heuvel,1 Jelle Vriend,2 Chee Ping Ng,1 Tom T. G. Nieskens,2 Vincent van Duinen,3
Bjorn de Wagenaar,1 Rosalinde Masereeuw,4 Laura Suter-Dick,5 Sebastiaan J. Trietsch,1 Martijn Wilmer,2
Jos Joore,1 Paul Vulto,1 and Henriette L. Lanz1,6
Received 3 April 2018; accepted 23 July 2018; published online 14 August 2018
Abstract. Proximal tubules in the kidney play a crucial role in reabsorbing and eliminating
substrates from the body into the urine, leading to high local concentrations of xenobiotics.
This makes the proximal tubule a major target for drug toxicity that needs to be evaluated
during the drug development process. Here, we describe an advanced in vitro model
consisting of fully polarized renal proximal tubular epithelial cells cultured in a microﬂuidic
system. Up to 40 leak-tight tubules were cultured on this platform that provides access to the
basolateral as well as the apical side of the epithelial cells. Exposure to the nephrotoxicant
cisplatin caused a dose-dependent disruption of the epithelial barrier, a decrease in viability,
an increase in efﬂuent LDH activity, and changes in expression of tight-junction marker zona-
occludence 1, actin, and DNA-damage marker H2A.X, as detected by immunostaining.
Activity and inhibition of the efﬂux pumps P-glycoprotein (P-gp) and multidrug resistance
protein (MRP) were demonstrated using ﬂuorescence-based transporter assays. In addition,
the transepithelial transport function from the basolateral to the apical side of the proximal
tubule was studied. The apparent permeability of the ﬂuorescent P-gp substrate rhodamine
123 was decreased by 35% by co-incubation with cyclosporin A. Furthermore, the activity of
the glucose transporter SGLT2 was demonstrated using the ﬂuorescent glucose analog 6-
NBDG which was sensitive to inhibition by phlorizin. Our results demonstrate that we
developed a functional 3D perfused proximal tubule model with advanced renal epithelial
characteristics that can be used for drug screening studies.
KEY WORDS: kidney-on-a-chip; nephrotoxicity; apparent permeability (Papp); proximal tubule;
transepithelial transport.
INTRODUCTION
Renal proximal tubules play a crucial role in reabsorbing
salt, water, and organic solutes such as glucose from the
glomerular ﬁltrate as well as eliminating endogenous and
exogenous waste products from the body (1). The
transepithelial transport of substrates and the concentration
of xenobiotics in the tubular lumen make the proximal tubule
a target for drug-induced toxicity (2).
Currently, preclinical assessment of nephrotoxicity is
mainly performed in animal studies. However, due to ethical
concerns and the limited translatability of these models to the
human situation, in vitro modeling is rapidly becoming
important for studying solute transport, drug-induced toxicity,
and disease-related kidney failure (3). Current-day in vitro
models typically comprise human renal proximal tubule
epithelial cells (RPTECs) grown on a permeable membrane
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support. But, these systems often lack elements such as ﬂow
or embedding in an extracellular matrix (ECM) structure and
are not compatible with image-based readouts. Moreover, the
permeable support membrane is a crucial barrier inﬂuencing
both transport parameters and physiology of cells.
In recent years, the use of microﬂuidics has gained
signiﬁcant interest for building human tissue models of
enhanced physiological relevance. These techniques, popu-
larly referred to as organ-on-a-chip, add ﬂow to cell culture
systems, enable gradient formation, facilitate a 3D architec-
ture of tissues, allow engineering of tissue complexity through
layered co-cultures, and are typically compatible with ECM-
embedded cultures. Various model systems for the renal
proximal tubule have been reported over the past few years
(4–7). Although they represent powerful examples of the
added value of microﬂuidics to the realm of in vitro kidney
modeling, these chips are largely prototypes, yield single data
points per chip, require external tube and pump connections
for each chip, and are typically constructed of materials that
absorb hydrophobic compounds (8).
The current challenge is to implement these prototypes
into platforms combined with protocols and assays for routine
use in an end-user environment (9,10). Robust cell culture
protocols are needed that can be performed in parallel in
order to test dilution series, including several replicates and
appropriate controls. Furthermore, the platform needs to be
compatible with a range of assays that are typically used in an
in vitro environment, including ﬂuorescence-based methods,
immunohistochemical staining, barrier integrity monitoring,
transport studies, viability assays, qRT-PCR, ELISAs, and
many others. Last but not the least, operation of the platform
should be straightforward to the level that expert microﬂuidic
skills are not required for end-users. Therefore, the organ-on-
a-chip platform needs to be compatible with standard lab
equipment such as pipets, (confocal) microscopes, plate
readers, and other microwell-plate compatible equipment.
In this research, we used the OrganoPlate (11), a
microtiter-plate-based microﬂuidic chip platform enabling 40
tissues per plate. A proximal tubule-on-a-chip was modeled
with renal proximal tubule epithelial cells (12) (RPTEC;
SA7K clone) grown as perfused tubules against an ECM.
The cells used for this study were developed and
characterized by Li et al. (12) and showed similar expression
levels of several uptake and efﬂux transporters when compared
to human primary proximal tubule cells. The RPTEC line
further showed improved uptake and efﬂux compared to the
HK-2 cell line, with a more sensitive detection of
nephrotoxicants. Two of the efﬂux transporters, P-glycoprotein
(P-gp) and multidrug resistance-associated protein 4 (MRP4),
showed high levels of expression. Furthermore, the morphology
of cell monolayers showed a typical cobblestone structure which
is important for tight barriers.
After optimization of growth conditions of RPTEC in
the OrganoPlate, tubules were analyzed for polarization of
the epithelial layer by immunostaining and barrier integ-
rity through a live ﬂuorescent dye assay. Next, the
platform was evaluated for its suitability in studying
(transepithelial) transport and drug-induced toxicity. The
technology can be implemented in every basic cell
laboratory with standard laboratory equipment and can
be assessed with multiplexed readouts.
MATERIALS AND METHODS
Cell Culture
Renal proximal tubule epithelial cells (RPTEC; Kidney
PTEC Control Cells, SA7K Clone, Sigma, Germany,
MTOX1030) were cultured on PureCol-coated (Advanced
BioMetrix, 5005-B, diluted with 1:30 in HBSS (Sigma H6648),
20 min incubation at 37°C) T75 ﬂasks in MEME alpha
Modiﬁcation (Sigma, M4526) supplemented with RPTEC
Complete Supplement (Sigma, MTOXRCSUP), L-glutamine
(1.87 mM, Sigma, G7513), gentamicin (28 μg/mL, Sigma,
G1397), and amphotericin B (14 ng/mL, Sigma, A2942). Cells
were incubated in a humidiﬁed incubator (37°, 5% CO2), and
every 2–3 days, the medium was changed. At 90–100%
conﬂuency, cells were washed with HBSS (Sigma, H6648),
detached with accutase (Sigma, A6964), pelleted (140 g,
5 min), and used for seeding in the OrganoPlate. Cells for
experiments were used up to passage 3.
OrganoPlate Culture
For all experiments, a three-lane OrganoPlate (Mimetas
BV, 4003 400B) with a channel width of 400 μm and a height
of 220 μm was used. 1.6 μL of extracellular matrix (ECM) gel
composed of 4 mg/mL collagen 1 (AMSbio Cultrex 3D
Collagen I Rat Tail, Cat. 3447-319 020-01), 100 mM HEPES
(Life Technologies, 15630), and 3.7 mg/mL NaHCO3 (Sigma,
320 S5761) was injected into the middle inlet (Fig. 1a) of all
40 chips. After a polymerization time of 20 min, 20 μL HBSS
was added on top of the collagen 1 and the plate was
incubated in a humiﬁed incubator at 37°C over night. After
polymerization of the ECM, the plate could be also stored in
a humiﬁed incubator (37°C) for up to a week. RPTEC were
detached and resuspended in medium at a concentration of
10 × 106 cells per mL. Two microliters of the cell suspension
(20 × 103 cells) was injected into each top inlet, followed by an
addition of 50 μL medium to the same well. For control chips,
2 μL of medium was injected into the top inlet instead of the
cell suspension. Subsequently, the OrganoPlate was placed
for 5 h at an angle of 70° in the incubator (37°C, 5% CO2,
humidiﬁed). After attachment of the cells, 50 μL of medium
was added to the top outlet, bottom inlet, bottom outlet
(Fig. 1a), and HBSS on the gel was removed. The
OrganoPlate was placed ﬂat in an incubator on an interval
rocker platform (± 7° angle, 8 min interval) enabling a
bidirectional ﬂow though the perfusion channels (see
Fig. 5S). At day 3, antibiotics (gentamycin and amphotericin
B) were removed from the medium. The medium was
replaced every 2–3 days. Forty-eight-hour toxicant exposures
were started at day 6; all other experiments were performed
at days 7, 8, 9, or 10. To show the effect of ﬂow in the system,
an OrganoPlate was taken off the rocker platform from day 1
to day 4. At day 4, the medium was refreshed and the plate
was rocked again under same conditions as the control
experiments.
Immunohistochemistry
RPTEC tubes were ﬁxed by replacing the medium with
3.7% formaldehyde (Sigma, 252549) in HBSS (Sigma,
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55037C) for 10 min. Tubules were washed with washing
solution (4% fetal bovine serum (Gibco, 16140-071) in HBSS)
and permeabilized (0.3% Triton X-100 (Sigma, T8787) in
HBSS for 10 min. Next, cells were incubated for 45 min in
blocking solution (2% FBS, 2% bovine serum albumin (BSA)
(Sigma, A2153), and 0.1% Tween 20 (Sigma, P9416) in
HBSS). Hereafter, cells were incubated with the primary
antibodies, diluted in blocking solution, for 60 min at room
temperature. Primary antibodies against Ms-a-ezrin (BD
Biosciences, 610602, 1:200), Ms-a-acetylated tubulin (Sigma,
T6793, 1:4000), Rb-a-Zonula occludens-1 (ZO-1) (Thermo
Fischer, 61-7300, 1:125, rabbit), Rb-a-Phospho-Histone
(H2A.X) (Cell Signaling Technology, 9718S, 1:200, rabbit),
mouse isotype (Life technologies, 86599), and rabbit isotype
(Life technologies, 86199) were used. Subsequently, cells
were washed three times with washing solution and then
incubated for 30 min at room temperature with secondary
antibodies Gt-a-Ms IgG (H+L) Alexa Fluor 555 (Life
Technologies, A21422, 1:250), Gt-a-Rb IgG (H+L) Alexa
Fluor 488 (Life Technologies, A32731, 1:250) diluted in
blocking solution. After washing the tubules three times,
nuclei were stained with DraQ5 (Abcam, ab108410, 1:1000)
or Nucblue-ﬁxed cell stain (Life Technologies, R37606, 2
drops/mL) or Actin red (Life Technologies, R37112, 2 drops/
mL) in the last washing step. Fluorescent images for the 3D
reconstructions were taken with the Leica SP5-Sted Confocal
Microscope. A z-stack of 220 μm with 2 μm between each
image plane was imaged with Alexa 488, Alexa 555, and
Alexa 647. Fluorescent images for the analysis of the protein
expression after a toxicant exposure were taken with the
ImageXpress® Micro Confocal High-Content Imaging Sys-
tem (Molecular Devices). A z-stack of 5 μm between each
image plane was imaged for DAPI, FITC, TRITC, and Cy5
channels. A maximum projection was created for depicting
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Fig. 1. Proximal tubule-on-a-chip model in the three-lane OrganoPlate platform. a Seeding RPTEC against
collagen 1: After loading collagen 1 into the middle channel, cells were seeded in the adjacent channel. By
gravity, cells are triggered to attach to the gel. After inducing ﬂow, RPTEC start growing a perfused tubular
structure. Dimensions of the channels are in micrometer. b Phase contrast images at day 0, day 4, and day 6
after seeding of RPTEC. Images show that RPTEC form a tubular structure in the top channel in 6 days.
Scale bar = 200 μm. c, d 3D reconstruction images of RPTEC tubules in the OrganoPlate showing a view
into the lumen of tubules (apical side). The magniﬁcation shows a single z-slice of the cells growing against
the ECM. Nuclei in blue. Scale bars = 30 μm. c Image of the tubule showing the presence of cilia (acetylated
tubulin, red) pointing into the direction of the lumen. The conﬂuent tubules express ZO-1 at the cell
borders which conﬁrms the tight junction formation between neighboring epithelial (green). d Ezrin
expression (red) on the apical side and ZO-1 (green) expression at the cell borders of the tubules shows the
correct polarization of the cells
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the images, and a summary projection was used for quanti-
fying the ﬂuorescent intensity of the markers.
Barrier Integrity Assay
The barrier integrity assay (BI assay) was performed by
replacing the medium of the perfusion channel with medium
containing 0.5 mg/mLTRITC-dextran (4.4 kDa, Sigma, FD20S)
and 0.5 mg/mL FITC-dextran (155 kDa, Sigma, T1287). Next,
the plate was imaged every 2 min for 12 min with the
ImageXpress Micro XLS-C High Content Imaging System
(Molecular Devices) at 37°C. Leakage of the dyes from the
apical side of the tube to the basal side into the ECM was
measured, and the ratio between the basal and the apical was
analyzed with Fiji (13). The labeled dextrans can be washed out
after each measurement. The permeability of the membranes
was analyzed by measuring the amount of molecules which
leaked though the membrane into the adjacent gel lane over
time. From these measurements, the apparent permeability
index (Papp: initial ﬂux of a compound through a membrane,
normalized by membrane surface area and donor concentra-
tion) was calculated by the following formula:
Papp ¼ ΔCreceiver  VreceiverΔtAbarrier  Cdonor
cm
s
 
ΔCreceiver is the measured normalized intensity difference
of the ECM to the donor channel (Fig. 2b value of D/value of
C) at t0 min and t10 min, Vreceiver is the volume of the measured
region in the ECM channel (Fig. 2b, c; channel height ×
channel width × channel length = 220 μm × 2304 μm ×
204.8 μm= 0.0001 cm2), Δt is the time difference t10 min −
t0 min = 10 min, Abarrier (0.0057 cm
2) is the surface of the ECM
interface with the medium channel, and Cdonor is the donor
concertation of the dextran dye (0.5 mg/mL) (Fig. 2c).
Cisplatin Exposure
To determine the toxic effect of cisplatin on RPTEC
tubules in the OrganoPlate, medium of both channels (apical
and basal) was replaced at day 6 after seeding with TOX
medium (MEME alpha Modiﬁcation (Sigma, M4526) supple-
mented wi th RPTEC Tox Supp lement (S igma ,
MTOXRTSUP), L-glutamine (1.87 mM, Sigma, G7513)) in
the presence of 0, 5, 15, 30, 90, 135, or 270 μM cisplatin
(Sigma, P4394, stock: 5 mM in 0.9% NaCl (Sigma, S7653) in
H20). After 48-h incubation on the rocker platform, phase
contrast images were taken and the medium was sampled
from the top channel. Samples from in- and outlet were
pooled and used for the LDH activity assay. Next, tubes were
incubated with WST-8 to determine cell viability. The barrier
integrity of the exposed tubules was assessed consecutively of
the WST-8 assay. After the exposures and viability measure-
ments, the tubules were ﬁxed with formaldehyde and stained
with H2A.X, actin, and ZO-1.
Lactate Dehydrogenase Activity Assay
Lactate dehydrogenase (LDH) activity of the samples
was determined using the Lactate Dehydrogenase Activity
Assay Kit (Sigma, MAK066) according to the manufacturer
protocol. In short, the medium of the top in- and top outlet
was pooled and 2 μL was added in duplicate to a 384 well
plate. In parallel, a concentration curve of the NADH
standard was added. Next, 18 μL LDH Assay Buffer was
added to all sample wells to bring to an initial volume of
20 μl. After a short centrifugation of the plate, 20 μl Master
Reaction Mix were added to each well and mixed on a
horizontal shaker in the plate reader. After 1 min, the
absorbance was measured at 450 nm. While the plate was
incubated, it was measured every 2 min until the value of the
most active sample was higher than that of the highest
standard (12.5 nmol/well). For the analysis, the LDH activity
was determined using the following formula
LDH activity ¼ B sample dilution factor
reaction timeð Þ  V
where B is the amount (nanomole) of NADH generated
between tinitial and tﬁnal, the reaction time is tﬁnal − tinitial (in
minutes), and V is the sample volume (in milliliters) added to
the well.
Cell Viability (WST-8 Assay)
The cell viability of the cells was determined using the Cell
Counting Kit—8 (Sigma, 96992). The WST-8 solution was
diluted 1:11 with TOX medium and added to the channels of
the OrganoPlate (30 μL in- and outlets). After 18 min on the
rocker platform and a 2-min ﬂat incubation, the absorbance in
the top in- and outlets was measured with the Multiskan™ FC
Microplate Photometer (Thermo scientiﬁc) at 450 nm.
Calcein-AM Efﬂux Inhibition
Medium in all perfusion channels was replaced with
1 μM calcein-AM (Life technologies, C3099, stock: 1 mM in
DMSO) in KHH buffer (Krebs-Henseleit (Sigma, K3753) +
10 mM HEPES (Gibco, 15630) adjusted to pH 7.4) in the
presence of 10 μM cyclosporin A (Sigma, 30024, stock 5 mM
in DMSO), 500 μM Digoxin (Fluka, 4599, stock 100 mM in
DMSO), or 0.5% DMSO (Sigma, D8418, vehicle control).
After a 60-min incubation on the rocker platform, chips were
washed one time with ice cold KHH buffer. In the next
washing step, Hoechst 33342 (2 drop/mL, Life Technologies,
R37605), 10 μM PSC833 (Sigma, SML0572, stock: 5 mM in
DMSO), 10 μM Ko143 (Sigma, K2144, stock 10 mM in
DMSO), and 10 μM MK571 (Sigma, M7571, stock 10 mM in
H2O) were added to the washing solution and the plate was
imaged with the ImageXpress® Micro Confocal High-
Content Imaging System.
MRP2/4 Efﬂux Inhibition
Medium in all perfusion channels was replaced with 1.25 μM
CMFDA (Molecular Probes, C7025, stock 2.5 mM in DMSO) in
the presence of 0, 10, 20, and 30 μMMK571 (Sigma, M7571, stock
10 mM in H2O) in KHH buffer. After a 30-min incubation on the
rocker platform, the chips were washed one time with ice cold
KHHbuffer. In the next washing step, Hoechst 33342 (2 drops/mL,
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Life Technologies, R37605), 10 μM PSC833 (Sigma, SML0572,
stock 5mM inDMSO), 10 μMKo143 (Sigma,K2144, stock 10mM
in DMSO), and 10 μMMK571 (Sigma, M7571) were added to the
washing solution and the plate was imagedwith the ImageXpress®
Micro Confocal High-Content Imaging System.
6-NBDG Inﬂux Inhibition
Medium in the apical channel (Fig. 1) was replaced with
OptiHBSS (1/3 Opti-MEM (Gibco, 11058-021), 2/3 HBSS
(Sigma, H6648)) containing 500 μM 6-(N-(7-Nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)-6-Deoxyglucose (6-NBDG, Molecular
Probes, N23106, lot 1704487, stock 10 mM in H2O) and 0, 20,
100, or 500 μM Phlorizin (Sigma, P3449, stock 200 mM in
Ethanol (JT Baker, 8025.2500PE)). All conditions contained
0.25% ethanol as vehicle. Medium in the basal channel was
replaced with 6-NBDG-free medium, concentrations of
phlorizin matched apical channel concentrations. After a 30-
min incubation on the rocker platform, cells were washed two
times with ice cold OptiHBSS. In the second washing step,
Hoechst 33342 (2 drops/mL, Life Technologies, R37605) was
added to the washing solution and the plate was imaged with
the ImageXpress® Micro Confocal High-Content Imaging
System.
Image Acquisition and Analysis of the Transport
Experiments
For the in-cell transport assays, plates were imaged with
the ImageXpress® Micro Confocal High-Content Imaging
System. A z-stack of 220 μm with 10 μm between each image
plane was imaged with the FITC and the DAPI channel (Fig.
S1). The intensity of the FITC signal of the cells growing
against the ECM was analyzed with Fiji (13) and corrected
for the background and cell number. Treated chips were
normalized against vehicle control.
Transepithelial Transport Assay
Medium in the apical channel was replaced with medium
containing 20 μM cyclosporin A or 0.4% DMSO. Medium in
the basal channel was replaced with TOX medium containing
10 μM rhodamine 123 (Sigma, 83702, stock 50 mM in
ethanol) together with 20 μM cyclosporin A or 0.4% DMSO.
To determine the concentration of rhodamine 123, a
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Fig. 2. Barrier integrity assay on tubular culture in the three-lane OrganoPlate platform. a The barrier integrity of the cell layer against the
ECM was examined by perfusing the lumen of the tubule with dextran dyes. In healthy, leak-tight tubules, dyes remain in the lumen, whereas
in leaky tubules, the dye enters the ECM channel. b The proportion of dye leaking through the tubule was monitored by measuring the
ﬂuorescence of the leaking dye into the gel. The gel channel intensity (FLECM) was normalized for the intensity of dye in the perfusion channel
(FLperf). c Vertical illustration of the dye in the lumen of the tubule. Abarrier is the area of the cell layer against the interface, Vreceiver (Vre) is the
volume of the ECM behind the barrier which receives the dye. d Fluorescent images of the 10-min time point. Images were taken at day 1, day
3, and day 6 after seeding of RPTEC. At day 1, tubules did not form a barrier yet, whereas at day 3, the barrier is already partially formed.
From day 6, the barrier is leak tight. e Apparent permeability (Papp) of the RPTEC tubules at different days. For all measurements, the same
chips were analyzed over time (n = 4). Error bars represent the standard deviation
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concentration curve was added to unused chips. Tubules were
incubated for 5 h on the rocker platform. After 3 h and after
5 h, rhodamine 123 concentration was measured by imaging
the top inlets with the FITC ﬁlter on the ImageXpress Micro
XLS-C High Content Imaging Systems. The apparent perme-
ability (Papp) was calculated by using the formula
Papp ¼ ΔCreceiver  VreceiverΔtA Cdonor
cm
s
 
:
Creceiver is the measured intensity difference in the top
wells between t3 h and t5 h, Vreceiver is the receiving volume in
the reservoirs of the top inlets, t is the time difference t5h −
t3h = 2 h, A is the surface of the ECM interface with the
medium channel, and Cdonor is the donor concertation of
10 μM rhodamine 123.
Flow Simulation and Experimental Verification
The platform described in this work uses a gravity-based
perfusion system. The ﬂuid ﬂow rate and induced shear stress in
the microﬂuidic channels of the OrganoPlate was estimated
using a numerical model simulated in Python (Python Software
Foundation, USA). This model calculates the induced pressure
difference between two volumes of ﬂuid, which are present in
two microtiter plate wells that are connected by a microﬂuidic
channel. The numerical model is described in more detail in the
supplementary information. To validate the numerical model of
the gravity-driven ﬂow in the OrganoPlate, absorption was
sequentially measured at 494 nm using a Fluorescein solution
(Sigma, 46960, 10 μg/mL in water). For the veriﬁcation, a
9603200BOrganoPlate (two-lane plate with 120 × 200 μm,w × h
channels) was used. The FITC solution was added to the
channel systemwith 50 μL in each in- and outlet. After tilting the
plate at a set angle, the ﬂuorescence of both wells was measured
and compared with the associated simulated volumes.
Statistics and Data Analysis
Images were analyzed using Fiji (13). Data analysis was
performed using Excel (Microsoft ofﬁce 2016) and GraphPad
Prism (GraphPad Software Inc., version 6.07). Error bars
represent the standard deviation. Data were analyzed using
one-way ANOVA followed by a Dunnett multiple compari-
son test which compares all treated chips to the control chips.
Comparisons of two groups were done using the t test. A p
value of < 0.05 was considered to be signiﬁcant. At least three
technical replicates per data point were obtained.
RESULTS
Development of a Proximal Tubule-on-a-Chip
The platform we used to develop perfused 3D proximal
tubules was the three-lane version of the OrganoPlate (Fig. 1a).
The top part of this plate is a standard 384-well plate with a
modiﬁed glass bottom. In the bottom of the OrganoPlate, 40
microﬂuidic chips are embedded. One chip consists of three 400-
μm-wide and 220-μm-high channels separated by ridges, the
phaseguides (14). First, an extracellular matrix (ECM) gel was
loaded to the middle channel of the OrganoPlate. The liqueﬁed
ECM entered the channels by capillary action and did not
overﬂow to the adjacent channel through meniscus pinning on
the phaseguide. The ECM is free-standing, allowing interroga-
tion of the epithelial barrier function without interference of an
artiﬁcial membrane. For the seeding procedure, a single cell
suspension of RPTEC was added to one of the adjacent
channels and cells could attach to the ECM by placing the plate
on its side, in vertical position (Fig. 1a). After attachment of the
cells, the plate was placed ﬂat on a rocking platform. By
positioning the in- and outlets of one chip on different heights,
liquid ﬂow was induced through the channels by leveling
between the reservoirs (Fig. S5a). Fluid ﬂows are bidirectional
and pulsatile. Flow proﬁles have been simulated and experi-
mentally veriﬁed (Fig. S5b). The change in ﬂuorescence due to
ﬂow of FITC solution between wells showed a high correlation
with the associated simulated volumes. Results show that mean
ﬂow rates of 2.02 μL/min could be achieved with amean shear of
0.13 dyne/cm2 (Fig. S5 c, d).
The seeding and culture conditions for proximal tubules-
on-a-chip based on RPTEC cells were optimized by testing
different settings for parameters, such as seeding density, ECM
composition, medium composition, and perfusion height and
angle. Figure 1b shows optimal tube formation of RPTEC over
time. As seen in Fig. S3, the ﬂow is crucial for the tubule
formation.Without any ﬂow, tubule formation is not possible. In
Fig. S4, the long-term viability of the RPTEC in the
OrganoPlate is depicted. RPTEC are stable in the OrganoPlate
up to day 11. After this time period, cells start invading theECM
which makes barrier-dependent assays impossible. Therefore, it
was decided to perform all assays from day 6 to day 10.
Proximal Tubules-on-a-Chip Form Polarized Tight Barriers
RPTEC tubules were cultured in the OrganoPlate for 7–
10 days. As depicted in Fig. 1c, RPTEC formed a tubular
structure with cells lining the ECM (curved part of the tubule)
and the walls of the channel, thus having an open, perfused
lumen. Conﬂuent tubules formed tight junctions as visualized by
the zona-occludence 1 tight junction (ZO-1) expression (15),
and display primary cilia visualized by acetylated tubulin
staining (16). A single cilium per cell was observed, located at
the apical side of the cell layer pointing towards the lumen of the
tubule (Fig. 1c). The tubules were also stained forEzrin (17) that
was expressed on the luminal side of the tubule (Fig. 1d). It is
thus conﬁrmed that the tubes are polarized in a correct manner,
with the lumen being the apical side (corresponding to the pre-
urine side in an in vivo situation) and the basal side being against
the extracellular matrix (corresponding to the blood side in and
in vivo situation).
Subsequently, the integrity of the epithelial barrier was
investigated. To this end, a ﬂuorescently labeled dextran was
administered to the lumen of the tube. Leakage of the
ﬂuorescent dextran from the perfusion channel into the gel
compartment was monitored and quantiﬁed in order to have
a measure for the integrity of the epithelial cell monolayer
(Fig. 2a–c). To monitor the tubule formation over several
days, a higher molecular weight dextran (150 kDa FITC) and
a lower molecular weight dextran (4.4 kDa TRITC) were
used and leakage was assessed at day 1 and 3 and 6 days after
seeding. At day 1, no barrier formation could be detected,
whereas at day 3 the tubes were partly leak-tight. At day 6,
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the tubules were fully leak-tight for both dyes (Fig. 2d). After
quantiﬁcation of the signal at day 6, the calculated Papp
(apparent permeability) of the tubules were 6 × 10−6 cm/s for
the 4.4 kDa dextran and 2 × 10−6 cm/s for the 150 kDa
dextran (Fig. 2e). A good barrier integrity of the tubule is
crucial for assessing transport and directional toxicity as it
allows interrogation and exposure of the apical and
basolateral sides independently from one another.
The Proximal Tubule-on-a-Chip Allows Nephrotoxicity
Assessment
Next, kidney tubules were assessed for toxicity response
to cisplatin. Cisplatin is an anti-cancer drug, which is used for
the treatment of tumors of the lung, ovary, testicles, and head
and neck (18). The main route of the excretion of cisplatin is
via the proximal tubules, which leads to a higher accumula-
tion of the drug in the cells compared to other organs (19).
Kidney tubules were exposed 6 days after seeding for 48 h to
cisplatin at concentrations ranging from 5 to 270 μM. The
toxic effect of cisplatin on the proximal tubules was deter-
mined through multiplexing several assays: phase contrast
imaging, barrier integrity assessment, WST-8 viability mea-
surement, LDH release and immunohistochemical staining of
tight junctions, DNA damage, and cytoskeleton integrity. The
morphology of the tubules was analyzed by phase contrast
imaging and visually started to change at 270 μM cisplatin
concentration; at lower concentrations, no signiﬁcant differ-
ences were observed (Fig. 3a). Cisplatin showed a dose-
dependent disruption of the barrier integrity of the tubes as
determined by leakage of ﬂuorescent dextran 4.4 kDa and
150 kDa (Fig. 3b, c) with a matching increase in calculated
Papp for both the small and large dextran (Fig. 3d).
In addition to measuring the impairment of the barrier
integrity of the tubules, the cell viability was assessed using the
live cell enzymatic activity WST-8 assay. A decrease in cell
viability was observed at cisplatin concentrations of 30 μM and
higher, which was reduced to approximately 76% compared to
the vehicle control at the highest concentration of 270 μM
(Fig. 3e). Consistent with this, a signiﬁcant increase in LDH
(lactate dehydrogenase) release into the lumen was detected at
cisplatin concentrations of 30 μM and higher (Fig. 3f). Immu-
nohistochemical analysis of the exposed tubules further con-
ﬁrmed the toxicity of cisplatin. At concentrations of 30 μM and
higher, cisplatin caused increased DNA-damage (detected by
H2A.X DNA-damage marker staining (20), Fig. 3g, h) and
reduced expression of ZO-1 protein in the tight junctions
(Fig. 3g, j). Changes in the actin cytoskeleton were observed
from 5 μM onwards (Fig. 3g, i).
Active Substrate Transport Across the Epithelial Membrane
The kidneys play a crucial role in eliminating drugs and
metabolic waste products through excretion into the urine
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Fig. 3. Toxicant readouts after 48-h cisplatin exposure. a Visual break down of the tube after 48 h of treatment at highest concentrations. Scale
bar = 100 μm. b, c Perfusion of the lumen in the top channel with a lower sized dextran dye of 4.4 kDa and a higher sized dextran dye of
150 kDa. From a concentration of 90 μM, the ECM behind the barrier is ﬁlled with dye, whereas at concentrations of 5 μM and 15 μM, no
difference compared to vehicle control can be seen. Scale bar = 200 μm. d For quantiﬁcation of the barrier function, the apparent permeability
(Papp) was calculated. For both dextran sizes, a signiﬁcant increase of the Papp could be detected from 90 μM (p < 0.0001) compared to vehicle
control. e To quantify viability of the cells, a WST-8 assay was used. WST-8 is reduced by the cells to an orange formazan product which can be
measured with an absorbance reader at 450 nm. Viability was signiﬁcantly reduced (p < 0.0001) from 30 μM compared to vehicle control. f
LDH activity in the medium indicated the number of dead cells. The LDH assay detected, similar to the WST-8 assay, a signiﬁcant effect of
cisplatin from 30 μM (p < 0.05). gMaximum projections or the immunostaining against H2A.X (DNA damage), actin (cytoskeleton), and ZO-1
(tight junction marker). Scale bar = 200 μm. h–j Fluorescent intensity analysis of the summary projections of DNA damage marker H2A.X,
actin cytoskeleton marker, and tight junction marker ZO-1. The intensity of all three markers is corrected for the background and nuclei count.
Graphs show data of three chips per condition. Error bars represent the standard deviation
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(21). Many compounds require active transport by dedicated
enzymes; the efﬁciency of which can be compromised by
different drugs (2,22).
To study the transporter functionality of kidney tubules
in the OrganoPlate, calcein-AM and CMFDA were used to
monitor P-gp and MRPs, respectively. These two trans-
porters, which transport substrates into the apical lumen,
are from the ATP-binding cassette family of transporters. P-
gp mainly transports cationic as well as unconjugated
xenobiotics whereas MRP is responsible for removing conju-
gated compounds from the body (22,23). Calcein-AM is a
substrate for P-gp which is often used to assess the
functionality of the transporter (23). Cell tracker reagent 5-
chloromethylﬂuorescein diacetate (CMFDA) is a compound
for the MRP transporters (24). Both compounds enter the
cells passively and are converted inside of the cells to the
green ﬂuorescent dyes calcein and GS-MF, respectively
(23,25). Cyclosporin A is an inhibitor of the P-gp transporter,
whereas digoxin, which is a medication used to treat various
heart conditions, is a substrate for P-gp (2) (Fig. 4a). MK571
is an inhibitor of the MRPs (2) (Fig. 4d).
To measure the inﬂuence of compounds on transport
activity in the proximal tubule-on-a-chip, we set up ﬂuores-
cent substrate-based activity assays (Fig. S1). For the analysis
of the uptake of ﬂuorescence inside of the cells lining the
ECM, a z-stack of the tubule was imaged, and planes of the
desired area are selected (Fig. S1e). After removal of the
signal from out-of-focus cells, stacks were compressed, and
the signal was integrated (Fig. S1f).
As both dyes enter the cells passively, RPTEC tubules
were exposed to the dyes as well as their respective inhibitors
from the apical as well as basal side. A 2.2 ± 0.1- or 1.5 ± 0.2-
fold increase in calcein accumulation was observed after co-
incubation with cyclosporin A or digoxin, respectively,
conﬁrming P-gp activity as both drugs competitively interact
with the efﬂux pump (Fig. 4b, c). To monitor MRP-function,
an efﬂux inhibitor cocktail of PSC833, MK571, and Ko143
was used to avoid redundancy of other transporters (23). A
dose-dependent inhibition of GS-MF efﬂux was observed
upon increasing MK571 concentrations, as shown in Fig. 4e,
conﬁrming MRP activity.
In addition to the efﬂux transporters, the glucose uptake
by the sodium-glucose-linked transporter SGLT2 (26,27) was
evaluated using the ﬂuorescent glucose analog 6-NBDG (28).
SGLT2-mediated inﬂux from tubular lumen into the cells was
sensitive to inhibition by the SGLT inhibitor phlorizin (29)
(Fig. 4f, g). This conﬁrms the presence and activity of the
SGLT2 transporter.
The Proximal Tubule-on-a-Chip Allows Transepithelial
Transport Assessment
To further examine the capability of transepithelial
transport across the epithelium of the 3D perfused proximal
tubules, the ﬂux of rhodamine123 from the basolateral to the
apical compartment was assessed. Rhodamine123 is a sub-
strate of P-gp, and its transport was analyzed in the absence
and presence of the transport inhibitor cyclosporin A (30).
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Fig. 4. Evaluation of P-gp, MRP, and SGLT2 transporter activity in proximal tubule-on-a-chip. aWhen the non-ﬂuorescent calcein-AM enters
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bars represent the standard deviation
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The experimental set-up is shown in Fig. 5a, b. Rhoda-
mine123 was administered to the basal perfusion channel and
measured in the perfusion medium on the apical side. In
order to have a highest signal-to-noise ratio, the ﬂuorescent
signal was measured in apical-side in- and outlet, where the
liquid column was largest. Inhibition of transport by cyclo-
sporine A reduced ﬂuorescence signal in the apical-side in-
and outlets as shown by representative images in Fig. 5c. It is
known that cyclosporin A has a toxic effect on the kidney.
Therefore, its effect on the barrier integrity was assessed. It
was found that a concentration of 20 μM cyclosporin A was
determined as safe as transport inhibitor, supported by the
absence of an effect on barrier integrity (Fig. S2). The Papp of
rhodamine123 changed from 3.4 × 10−5 ± 0.1 × 10−5 cm/s
without inhibitor to 2.2 × 10−5 ± 0.1 × 10−5 cm/s with
cyclosporin A, indicating (inhibition of) active transport
(Fig. 5d). This is a clear demonstration that transepithelial
transport can be assessed in the system.
DISCUSSION AND OUTLOOK
We reported the development of a functional proximal
tubule-on-a-chip model which can be implemented for
routine assessment of kidney toxicity and drug-drug interac-
tion studies. The OrganoPlate platform allows parallel culture
and assessment of 40 independent kidney tubules. This is
important in toxicological studies or in compound testing as it
allows for proper controls, replica’s, and dilutions series.
Induction of ﬂow is realized by passive leveling on an interval
rocker system, which is an easy to use alternative to complex
pump solutions. Other than the rocking platform, no further
specialized lab equipment is needed. As the format of the
platform is a standard microtiter layout of a 384-well plate, it
is fully compatible with most readers, microscopes, and robot
handling equipment. The platform is fully pipet operated and
media changes as well as reagent additions are non-invasive.
Physiologically relevance of the system is enhanced by
culturing epithelial cells directly against an extracellular
matrix (ECM) mimic in a manner that is free of artiﬁcial
membranes, under application of perfusion ﬂow and by
mimicking the 3D morphology.
A critical aspect in the concept is the selective patterning
of extracellular matrix in the chips. In order to do this, surface
tension techniques have been employed that allow selective
ECM priming using pipetting means only. As a consequence
thereof, only part of the tube is exposed to the ECM (curved
part). This does not hamper the measurement results as the
barrier and the rhodamine transport assay exclusively con-
sider the cell layer against the extracellular matrix. Other
systems are known from literature that have full ECM
embedment (31); however, such systems come at the cost of
throughput and ease of handling, as it is impossible to create
a lumen in an ECM gel with pipetting steps only.
Similar choices were made with respect to the dimen-
sions of the proximal tubule. In this study, the diameter of the
tubules is 400 μm, which is signiﬁcantly larger than the in vivo
proximal tubules (approximately 60 μm (32)). However, the
choice for larger dimensions allowed a greater sensitivity of
assays, particularly those that are executed off-chip.
We showed the multiplexing assays in a microﬂuidic
format. The barrier integrity could be monitored in real time
by adding a reporter dye. In parallel, cellular enzymatic
activity (WST-8) and LDH release could be measured. All
three assays yielded a similar result to cisplatin exposure,
indicating the robustness of the model. Immunohistochemical
staining was also used in a multiplex manner for assessment
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Fig. 5. Transepithelial transport of rhodamine 123. a Ten micromolar of rhodamine 123 was added solely to the basal side of the tubule with or
without 20 μM cyclosporin A present at both sides of the tube. b After 3 and 5 h, images were taken from the inlets guiding to the lumen of the
tubule (blue squares: measured wells). The intensity above the glass bottom of the wells was measured (orange square: area selection). To
determine the concentration of rhodamine 123 in the top wells, spiked samples were added to empty chips on the same plate and analyzed. The
resulting concentrations were used to calculate the Papp of the transport of rhodamine 123. c Images of the top in- and outlets or the
OrganoPlate show the apical ﬂuorescent signals after 5-h incubation of rhodamine 123 on the basal side of the tubule. A decreased ﬂuorescent
signal was observed after co-incubation with cyclosporin A, as shown in the top inlets. −: without transport inhibition, +: with 20 μM
cyclosporin A addition (apical and basal). d A signiﬁcant decrease in Papp was observed when adding rhodamine 123 together with 20 μM
cyclosporin A. ****p < 0.0001. Data are combined from two independent experiments with ﬁve to nine chips per plate and per condition. Error
bars represent the standard deviation
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of the effect of cisplatin on the tight junctions (ZO-1),
cytoskeleton (actin), and DNA damage (H2A.X). Although
some showed higher sensitivity than the live assays, the stains
represent an end-point assay and require much more effort to
execute properly. Moreover, only a limited number of stains
could be multiplexed in the same model, requiring replica’s to
be used for different analyses.
The multiplexed live assays used for acute kidney toxicity
detection here are compatible with chronic toxicity assessments.
For example, the barrier integrity assays were previously used to
study 5-day exposure of gut tubules to toxicants (33). Non-
invasive assays are important to study chronic effects of drugs
that only exert negative effects after prolonged use. The
proximal tubule model developed here together with
multiplexed assays and the possibility for repeated dosing of
the model allows for future longitudinal studies.
In this publication, we used the microﬂuidic system for
growing tubular structures. In addition to that, other cell
types can be embedded into the ECM. An example of
functional 3D networks of neurons and glia embedded in
the ECM of one channel with an adjacent medium channel is
shown by Wevers et al. (34), and Lanz et al. studied the
behavior of breast cancer cells grown in an ECM (35). The
method of culturing cells embedded in the ECM can be easily
combined with the model presented here: instead of culturing
the RPTEC against a pure ECM, supporting cells can be
added into the ECM. In addition to this, the complexity of the
model could be further increased by growing an endothelial
tubule in the basal-side perfusion channel. Ultimately, we aim
to combine endothelium, ﬁbroblasts, and podocytes to have a
fully functional kidney-on-a-chip model.
We showed two different possibilities to monitor the
transport of the proximal tubules. First, we measured and
analyzed the signal of compounds retained by the cells lining
the ECM layer. Second, we showed feasibility of
transepithelial transport studies on the RPTEC containing
tubules using the ﬂuorescent substrate, rhodamine123. Both
types of experiments show clear transporter functionality,
whereas the latter is the most complex functional assay. We
have not assessed organic anion transporter (OAT) expres-
sion by the RPTEC used in this study, but 2D evaluation by
Suter-Dick et al. (36) showed no response to tenofovir,
indicating absence of the OAT1 transporter. This limits the
use of the cell line for assessment of transport of organic ions.
To compensate for this, we also implemented a cell line
overexpressing the organic anion transporter 1 (ciPTEC,
(Vriend et al. 37)). In future work, we will compare the
performance of both cell models in response to a range of
blinded compounds.
For future studies, transport capabilities will be shown also
for non-ﬂuorescent substrates. To achieve this goal, radiolabeled
compounds or mass spectrometry can be used to analyze and
quantify transport. In this manner, a much wider range of
compounds and transporter functionality can be investigated.
These off-plate assays will require sampling of the perfusate
instead of the microscope-based readouts used here. The use of
microﬂuidic chips requires limited amounts of cells andmedium,
which is positive in the light of use of valuable materials with
restricted access. However, for certain analysis methods, the
small sample volumes could be limiting. Detection of
transported compounds will depend on the sensitivity of the
analysis method (e.g., mass spectrometry). Other off-plate
analyses as for example qRT-PCR are feasible through pooling
of chip lysates. Such functional assays will be of great support for
in vitro to in vivo extrapolation.
In summary, we developed a user-friendly, functional
kidney-on-a-chip model that can be used to study the effect of
compounds in 40 parallel cultured renal tubules. The tubules
could be assessed for barrier function by ﬂuorescent imaging
and multiplexed with a range of assays including viability, LDH
leakage, and immunohistochemical staining. In addition, trans-
porter activity was shown by means of transport inhibition
studies for both substrate uptake, as well as transcellular
transport. The functionality of the platform in combination with
the ease of handling and decent throughput makes this a useful
platform for studying nephrotoxicity, compound excretion,
drug-drug interaction studies, and disease mechanisms.
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